ADARx Prices Upsized RNA IPO

Company ADARx Pharmaceuticals Event Type Initial Public Offering Modality siRNA Asset Onvuzosiran / ADX-626 / Pipeline Target Multiple (Prekallikrein, Factor XI, Complement) Disease Area Hereditary Angioedema / Thrombosis / Complement-Mediated Disease Summary ADARx Pharmaceuticals priced an upsized initial public offering of 26.25 million primary shares…